Semax and BDNF: separating the Russian clinical literature from the hype

LTLeo Tanaka· 20 days ago

Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.

Semax is fascinating because it has a real clinical history in Russia for stroke and cognitive indications, but the independent Western randomized-trial base is thin. A lot of the BDNF and NGF claims trace back to mechanistic and animal work plus clinical use that has not been widely replicated under blinded conditions.

I think the fair read is Tier 2: more human signal than the pure research peptides, but well short of the replicated RCT evidence we have for the GLP-1 drugs. Curious what the researchers here think about the quality of the original studies.

1 Reply

DCDr. Sarah Chen researcher· Expert· 19 days ago

Tier 2 is the fair characterization. The challenge with the Russian literature is that a lot of it is difficult to appraise independently due to access, language, and methodology reporting. There is more human signal than the pure research peptides, but it falls well short of replicated blinded RCTs.